Josh Nathan-Kazis is a reporter who covers a wide range of topics, with a focus on finance and business. His work has been featured in publications such as Yahoo Finance, Barron's, MarketWatch, and Cigalah Group. Josh provides insightful analysis and reporting on stock market trends, healthcare, and other relevant news impacting the business world.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Josh Nathan-Kazis primarily focuses on investment analysis and data-driven reporting within the healthcare and pharmaceutical industry in the United States. He seems to be interested in providing insights into stock performance, market trends, and major company developments.
If you have expert knowledge in the healthcare or pharmaceutical sectors with a focus on stocks, earnings reports, FDA approvals, or other related financial aspects of these industries, your input could be valuable for Josh's coverage.
Consider offering data-backed insights or exclusive information regarding major companies' financial performance or regulatory developments within the U.S. healthcare sector when reaching out to him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Drug company Pfizer is seeking to expand the approval of its respiratory syncytial virus vaccine to include adults over the age of 18.
By: Josh Nathan-Kazis
Drug company Pfizer is seeking to expand the approval of its respiratory syncytial virus vaccine to include adults over the age of 18.
By: Josh Nathan-Kazis
view original post 1 hour ago Bird Flu Isn't Killing Cows. The Experts Are Still Worried. By Josh Nathan-Kazis
By: Josh Nathan-Kazis
Vertex Pharmaceuticals is taking a big swing to secure its own second act: Late Wednesday, it announced a $4.9 billion deal to buy Alpine Immune Sciences which is developing a drug to treat a rare kidney disease. Vertex said it would pay $65 per share for Alpine, a 38.2% premium over the stock’s Wednesday closing price of $47.04. Shares of Alpine were trading at $64.19 early Thursday, while Vertex shares were up 1.2%.
Analysts attribute much of that underperformance to lingering worries over the talc cases. Advertisement
By: Josh Nathan-Kazis
A complicated earnings report will cap a mess of a quarter for UnitedHealth Group on Tuesday morning, after a hack of the payments tools operated by its subsidiary Change Healthcare led to chaos and financial crisis across the healthcare industry. The hack was only one of a number of worrying developments for the healthcare giant the past few months, including a Wall Street Journal report that the Justice Department had launched an antitrust investigation. Meanwhile, health insurers across the sector have weathered worries over higher health spending by seniors, which sparked selloffs in January and raised questions about the long-term profitability of the Medicare Advantage programs that attracted companies such as Humana and UnitedHealth in recent years.
By: Josh Nathan-Kazis
The healthcare giant reports better-than-expected results for its messy first quarter, which included a damaging cyberattack.
By: Josh Nathan-Kazis
Pharmaceuticals company Johnson & Johnson kicked off earnings season for the sector. Investors want executives to put to rest ongoing talc litigation.
By: Josh Nathan-Kazis
Healthcare giant UnitedHealth Group reported better-than-expected earnings for a messy first quarter, which included a cyberattack on a unit’s payments tools.
After a sell off that saw its shares fall nearly 20% this year, the biotech Gilead Sciences turned in first-quarter results on Thursday that were slightly better than anticipated. Sales for the quarter were $6.7 billion, beating the analyst consensus estimate as calculated by FactSet which was $6.4 billion. The company reported a loss for the quarter of $1.32 per share, better than the FactSet consensus estimate of a loss of $1.49 per share.
(833) 317-6278 
